132 related articles for article (PubMed ID: 3512715)
1. Invariant chain associates with HLA class II antigens via its extracytoplasmic region.
Marks MS; Cresswell P
J Immunol; 1986 Apr; 136(7):2519-25. PubMed ID: 3512715
[TBL] [Abstract][Full Text] [Related]
2. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
3. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens.
Machamer CE; Cresswell P
J Immunol; 1982 Dec; 129(6):2564-9. PubMed ID: 6982931
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the biosynthesis of HLA-DR glycoproteins in human malignant melanoma cell lines.
Lloyd KO; Ng J; Dippold WG
J Immunol; 1981 Jun; 126(6):2408-13. PubMed ID: 6785352
[TBL] [Abstract][Full Text] [Related]
5. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
6. The invariant chain is a phosphorylated subunit of class II molecules.
Spiro RC; Quaranta V
J Immunol; 1989 Oct; 143(8):2589-94. PubMed ID: 2507633
[TBL] [Abstract][Full Text] [Related]
7. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the N-linked glycopeptides of DQw1 and DR1 molecules.
Iturbe S; Narasimhan S; Merrick JM; Falk JA; Letarte M
J Immunol; 1986 Jun; 136(12):4588-95. PubMed ID: 3486905
[TBL] [Abstract][Full Text] [Related]
10. Structure, biosynthesis, and polymorphism of chicken MHC class II (B-L) antigens and associated molecules.
Guillemot F; Turmel P; Charron D; Le Douarin N; Auffray C
J Immunol; 1986 Aug; 137(4):1251-7. PubMed ID: 2942601
[TBL] [Abstract][Full Text] [Related]
11. Monensin prevents terminal glycosylation of the N- and O-linked oligosaccharides of the HLA-DR-associated invariant chain and inhibits its dissociation from the alpha-beta chain complex.
Machamer CE; Cresswell P
Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1287-91. PubMed ID: 6608726
[TBL] [Abstract][Full Text] [Related]
12. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
Khalil H; Brunet A; Thibodeau J
J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
[TBL] [Abstract][Full Text] [Related]
13. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR antigens of autologous melanoma and B lymphoblastoid cell lines: differences in glycosylation but not protein structure.
Alexander S; Hubbard SC; Strominger JL
J Immunol; 1984 Jul; 133(1):315-20. PubMed ID: 6609984
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic cleavage of Ii to p25.
Thomas LJ; Nguyen QV; Elliott WL; Humphreys RE
J Immunol; 1988 Apr; 140(8):2670-4. PubMed ID: 3282009
[TBL] [Abstract][Full Text] [Related]
16. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.
Roche PA; Marks MS; Cresswell P
Nature; 1991 Dec; 354(6352):392-4. PubMed ID: 1956401
[TBL] [Abstract][Full Text] [Related]
17. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
Monji T; McCormack AL; Yates JR; Pious D
J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
[TBL] [Abstract][Full Text] [Related]
18. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
19. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
Lamb CA; Cresswell P
J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
[TBL] [Abstract][Full Text] [Related]
20. Biosynthetic intermediates of HLA class II antigens from B lymphoblastoid cell lines.
Kelner DN; Cresswell P
J Immunol; 1986 Oct; 137(8):2632-9. PubMed ID: 3489770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
